CoChat

Development and validation of a trans-ancestry polygenic risk score for type 2 diabetes in diverse populations

Open access
Ge, Tian, Irvin, Marguerite R., Patki, Amit, Srinivasasainagendra, Vinodh, Lin, Yen-Feng, Tiwari, Hemant K., Armstrong, Nicole D., Benoit, Barbara, Chen, Chia-Yen, Choi, Karmel W., Cimino, James J., Davis, Brittney H., Dikilitas, Ozan, Etheridge, Bethany, Feng, Yen-Chen Anne, Gainer, Vivian, Huang, Hailiang, Jarvik, Gail P., Kachulis, Christopher, Kenny, Eimear E., Khan, Atlas, Kiryluk, Krzysztof, Kottyan, Leah, Kullo, Iftikhar J., Lange, Christoph, Lennon, Niall, Leong, Aaron, Malolepsza, Edyta, Miles, Ayme D., Murphy, Shawn, Namjou, Bahram, Narayan, Renuka, O’Connor, Mark J., Pacheco, Jennifer A., Perez, Emma, Rasmussen-Torvik, Laura J., Rosenthal, Elisabeth A., Schaid, Daniel, Stamou, Maria, Udler, Miriam S., Wei, Wei-Qi, Weiss, Scott T., Ng, Maggie C. Y., Smoller, Jordan W., Lebo, Matthew S., Meigs, James B., Limdi, Nita A., Karlson, Elizabeth W. · 2022 · Genome Medicine
Cited by 173

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Abstract

Background: Type 2 diabetes (T2D) is a worldwide scourge caused by both genetic and environmental risk factors that disproportionately afflicts communities of color. Leveraging existing large-scale genome-wide association studies (GWAS), polygenic risk scores (PRS) have shown promise to complement established clinical risk factors and intervention paradigms, and improve early diagnosis and prevention of T2D. However, to date, T2D PRS have been most widely developed and validated in individuals of European descent. Comprehensive assessment of T2D PRS in non-European populations is critical for equitable deployment of PRS to clinical practice that benefits global populations. Methods: We integrated T2D GWAS in European, African, and East Asian populations to construct a trans-ancestry T2D PRS using a newly developed Bayesian polygenic modeling method, and assessed the prediction accuracy of the PRS in the multi-ethnic Electronic Medical Records and Genomics (eMERGE) study (11,945 cases; 57,694 controls), four Black cohorts (5137 cases; 9657 controls), and the Taiwan Biobank (4570 cases; 84,996 controls). We additionally evaluated a post hoc ancestry adjustment method that can express the polygenic risk on the same scale across ancestrally diverse individuals and facilitate the clinical implementation of the PRS in prospective cohorts. Results: The trans-ancestry PRS was significantly associated with T2D status across the ancestral groups examined. The top 2% of the PRS distribution can identify individuals with an approximately 2.5–4.5-fold of increase in T2D risk, which corresponds to the increased risk of T2D for first-degree relatives. The post hoc ancestry adjustment method eliminated major distributional differences in the PRS across ancestries without compromising its predictive performance. Conclusions: By integrating T2D GWAS from multiple populations, we developed and validated a trans-ancestry PRS, and demonstrated its potential as a meaningful index of risk among diverse patients in clinical settings. Our efforts represent the first step towards the implementation of the T2D PRS into routine healthcare.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13073-022-01074-2

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Cited by

See all 173

Metadata

Authors
Ge, T., Irvin, M. R., Patki, A., Srinivasasainagendra, V., Lin, Y.-F., Tiwari, H. K., Armstrong, N. D., Benoit, B., Chen, C.-Y., Choi, K. W., Cimino, J. J., Davis, B. H., Dikilitas, O., Etheridge, B., Feng, Y.-C. A., Gainer, V., Huang, H., Jarvik, G. P., Kachulis, C., Kenny, E. E., Khan, A., Kiryluk, K., Kottyan, L., Kullo, I. J., Lange, C., Lennon, N., Leong, A., Malolepsza, E., Miles, A. D., Murphy, S., Namjou, B., Narayan, R., O’Connor, M. J., Pacheco, J. A., Perez, E., Rasmussen-Torvik, L. J., Rosenthal, E. A., Schaid, D., Stamou, M., Udler, M. S., Wei, W.-Q., Weiss, S. T., Ng, M. C. Y., Smoller, J. W., Lebo, M. S., Meigs, J. B., Limdi, N. A., & Karlson, E. W.
Venue
Genome Medicine
Published
2022-06-29
Volume
14
Issue
1
Pages
70-70
ISSN
1756-994X (ISSN-L)
OpenAlex
W4283712790
Cited by
173
References
21
FWCI
19.25
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Development and validation of a trans-ancestry polygenic risk score for type 2 diabetes in diverse populations. https://app.cochat.ai/papers/10.1186/s13073-022-01074-2
The paper
Ge, T., Irvin, M. R., Patki, A., Srinivasasainagendra, V., Lin, Y.-F., Tiwari, H. K., Armstrong, N. D., Benoit, B., Chen, C.-Y., Choi, K. W., Cimino, J. J., Davis, B. H., Dikilitas, O., Etheridge, B., Feng, Y.-C. A., Gainer, V., Huang, H., Jarvik, G. P., Kachulis, C., . . . Karlson, E. W. (2022). Development and validation of a trans-ancestry polygenic risk score for type 2 diabetes in diverse populations. Genome Medicine. https://doi.org/10.1186/s13073-022-01074-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.